Combined Insulin Pump Therapy with Real-Time Continuous Glucose Monitoring Significantly Improves Glycemic Control Compared to Multiple Daily Injection Therapy in Pump Naïve Patients with Type 1 Diabetes; Single Center Pilot Study Experience

Lee, Scott W.; Sweeney, Tom; Clausen, Debbie; Kolbach, Celia; Hassen, Allen; Firek, Anthony; Brinegar, Charles H.; Petrofsky, Jerrold S.

doi:10.1177/193229680700100313

Cited by 20 publications

(16 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four trials of CGM compared the pump with CGM against MDI with SMBG, which confounds things [Hermanides et al (Eurythmic trial), 68 Lee et al, 69 Peyrot and Rubin, 70 Bergenstal et al (STAR-3) 71 ]. The durations of these trials were only 6, 3.5, 3.7 and 12 months, respectively.…”

Section: New Developmentsmentioning

confidence: 99%

A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial

Heller

White

Lee

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: journals.library@nihr.ac.ukThe full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Health Technology Assessment journalReports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.Reviews in Health Technology Assessment are termed 'systematic' when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others. HTA programmeThe HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta This reportThe research reported in this issue of the journal was funded by the HTA programme as project number 08/107/01. The contractual start date was in June 2011. The draft report began editorial review in March 2016 and was accepted for publication in July 2016. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. Published by the NIH...

show abstract

Section: New Developmentsmentioning

confidence: 99%

A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial

Heller

White

Lee

et al. 2017

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Their recommendations highlight the need for well-conducted RCTs of intensive insulin therapy delivery and glucose-monitoring approaches focusing on young children with T1DM, pregnant women with pre-existing diabetes, and particularly in elderly Comparative Effectiveness of Sensor-Augmented Pumps Versus MDI/SMBG Four RCTs, including 2 good quality studies, evaluated the effects of sensor-augmented pumps (rt-CGM + CSII) versus MDI/SMBG in children and adults with T1DM. [66][67][68][69] All studies provided training and used the MM Paradigm REALTime system; however, the frequency and intensity of follow-up visits differed between studies. [66][67][68][69] The mean baseline A1c in all studies was 8.6%, and participants were treated in the intervention groups for 15 weeks to 1 year.…”

Section: ■■ Future Research Directionsmentioning

confidence: 99%

“…[66][67][68][69] All studies provided training and used the MM Paradigm REALTime system; however, the frequency and intensity of follow-up visits differed between studies. [66][67][68][69] The mean baseline A1c in all studies was 8.6%, and participants were treated in the intervention groups for 15 weeks to 1 year.…”

Section: ■■ Future Research Directionsmentioning

confidence: 99%

“…[66][67][68][69] In addition, the review found that patients who used the sensor-augmented pumps spent significantly less time with hyperglycemia than patients with MDI/SMBG based on 2 of the 4 trials (P < 0.001; moderate strength of evidence). 66 However, the incidence of severe hypoglycemia and time spent in nonsevere hypoglycemia did not differ between the 2 intervention groups (moderate strength of evidence).…”

Section: ■■ Future Research Directionsmentioning

confidence: 99%

See 1 more Smart Citation

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Golden¹,

Sapir²

2012

JMCP

View full text Add to dashboard Cite

, before training in internal medicine and endocrinology and metabolism at the Johns Hopkins Hospital. During her fellowship in endocrinology, she received a master of health science degree in clinical epidemiology from the Johns Hopkins University Bloomberg School of Public Health. Her primary research interest centers around identifying endocrine risk factors associated with the development of diabetes and cardiovascular disease through the incorporation of measures of hormonal function into the design of clinical trials of cardiovascular risk modification, observational studies of incident cardiovascular disease and diabetes, and studies evaluating diabetic complications. Her current research focuses on studying the neuroendocrine response to chronic psychological stress as a risk factor for diabetes and cardiovascular disease. Dr Supplement Policy Statement Standards for Supplements to the Journal of Managed Care PharmacySupplements to the Journal of Managed Care Pharmacy are intended to support medical education and research in areas of clinical practice, health care quality improvement, or efficient administration and delivery of health benefits. The following standards are applied to all JMCP supplements to ensure quality and assist readers in evaluating potential bias and determining alternate explanations for findings and results. 1. Disclose the principal sources of funding in a manner that permits easy recognition by the reader. 2. Disclose the existence of all potential conflicts of interest among supplement contributors, including financial or personal bias. 3. Describe all drugs by generic name unless the use of the brand name is necessary to reduce the opportunity for confusion among readers. 4. Identify any off-label (unapproved) use by drug name and specific off-label indication. 5. Strive to report subjects of current interest to managed care pharmacists and other managed care professionals. S15 References Target AudiencesThis CME activity is designed to meet the educational needs of physicians, pharmacists, nurses, and case managers involved in the management and care of patients with diabetes. Learning ObjectivesBased on the findings from the Agency for Healthcare Research and Quality' s (AHRQ) comparative effectiveness review of insulin delivery and glucose-monitoring modalities for diabetes, participants should be able to: 1. Compare the benefits of insulin delivery systems in improving clinical outcomes, glycemic control, hypoglycemia, and quality of life in diabetic patients receiving intensive insulin therapy 2. Evaluate the differential effect of glucose-monitoring approaches on the process measures and intermediate and clinical outcomes in diabetic patients receiving intensive insulin therapy 3. Apply the AHRQ findings to guide effective, patient-centered clinical decisions Funding There is no fee for this CME/CE activity. This learning activity was prepared and funded under contract HHSA290201000006G from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Hea...

show abstract

“…This discovery is in accordance with other investigations which have confirmed the superior efficacy of the Lispro insulin analog in external pumps (Humalog) 26 . Continuous glucose monitoring (CGM) during insulin pump therapy appears to be an excellent alternative for further improvement of metabolic compensation [27][28][29][30][31][32] . The advantage of this compensation control is that it enables the patient to register both average 24-hour glycemia and variability in glycemia.…”

Section: Discussionmentioning

confidence: 99%

Benefits of Three-Month Continuous Glucose Monitoring for Persons With Diabetes Using Insulin Pumps and Sensors

Peterson¹,

Zapletalová²,

Kudlová³

et al. 2009

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Combined Insulin Pump Therapy with Real-Time Continuous Glucose Monitoring Significantly Improves Glycemic Control Compared to Multiple Daily Injection Therapy in Pump Naïve Patients with Type 1 Diabetes; Single Center Pilot Study Experience

Abstract: In this pilot study, the Paradigm REAL-Time System was initiated safely and effectively in type 1 diabetes patients who were pump naïve using a stepwise educational protocol.

Cited by 20 publications

References 19 publications

A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial

A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial

Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

Benefits of Three-Month Continuous Glucose Monitoring for Persons With Diabetes Using Insulin Pumps and Sensors

Contact Info

Product

Resources

About